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The Opioid Epidemic 
• Abuse of opioid medications became a nationwide concern 
beginning in the 1990s1,2
• The US Department of Health and Human Services (HHS) 
attributes the overprescription of opioids to drug industry 
misinformation regarding their potential for abuse
• Led to surge in abuse of non-prescription opioids such as 
heroin and fentanyl
• Approximately 2 million Americans were estimated to have 
had an opioid use disorder in 2017
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Opioid Abuse in Georgia 
• Opioid overdose deaths in Georgia have risen sharply since the 
start of the opioid crisis3
• Heroin deaths continue to increase
• Heroin is often taken via injection, particularly among rural users4,5
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Injection Drug Use, HIV, and HCV 
• The opioid epidemic may impact Georgia patients living with 
HIV and HIV + HCV6,7
– Heroin mortality is on the rise in Georgia
– Injection drug use increases risk of HCV and HIV 
transmission
– HCV epidemic is fueled by injection drug use
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Investigation
• How has the rise in injection drug use impacted patients 
living with HIV and both HIV and HCV in Chatham and 
surrounding areas? 
• Query
– Poisoning by opioids diagnosis 
• Poisoning diagnosis + HIV diagnosis 
• Poisoning diagnosis + HIV diagnosis + HCV 
diagnosis 
– Mortality rates 
– Demographic data
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Memorial Health University Medical Center 
(MHUMC) 
• 612 bed hospital in 
Savannah
• Opened in 1955 
• Serves 35 mostly rural 
counties across Southeast 
Georgia and South Carolina 
• Level 1 trauma center  -
resource for rural residents 
• Teaching hospital – Mercer 
University School of 
Medicine 
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The CARE Initiative 
• The CARE Initiative is an HIV and HCV screening and linkage to care 
program at MHUMC
• The CARE Initiative screens about 16,000 ED patients annually 
• Electronic health record (EHR) –based screening system based in 
MHUMC Emergency Department (ED) since 2016 
• Qualifying patients for HIV and HCV testing are 13+ years of age, HIV 
and/or HCV negative, and have not been tested in the past 12 months 
• HIV screening is out-opt using a verbal prompt 
• Reactive antibody (HCV) and/or antibody/antigen (HIV) labs 
automatically reflex to confirmatory testing 
• Patients diagnosed with HIV and/or HCV are contacted, notified and 
linked to care
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Methods
• Retrospective chart review using ICD-10 codes8,9
– Query of discharge data, 5-1-16 through 5-31-19 
• ICD-10 codes 
– ICD coding is the global standard for classifying patient diagnoses in 
medical charts
– Resource for morbidity and mortality data  
– T40 codes describe poisoning and adverse effects of narcotics and 
psychodysleptics 
• Opioids are narcotics 
• Different T40 codes describe opium, heroin, and other drugs 
– e.g., T40.0X2 = “Poisoning by opium, intentional self-harm” 
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Methods, continued
• ICD codes 
– HIV codes 
• Z21 (asymptomatic HIV) 
• B20 (known, symptomatic HIV) 
• B97.35 (HIV 2) 
– HCV codes
• B17.1 (acute hepatitis C) 
• B19.2 (unspecified hepatitis C) 
• B18.2 (chronic hepatitis C) 
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Results 
• 1342 opioids codes
– ~1.3 /day 
– 15 total mortalities 
• 25 opioids + HIV  
• 7 opioids + HIV + HCV  
• 60 opioids + HCV  
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Results: Demographics 
• White 63% 
• Black or African 
American 35% 
• American Indian or 
Alaska Native .15% 
• Asian .15% 
• Other .15% 
• Unknown/Decline 
to Specify 2% 
This research was supported (in whole or in part) by HCA and/or an HCA affiliated entity. The views expressed in this publication represent those of the 
author(s) and do not necessarily represent the official views of HCA or any of its affiliated entities. Screening program efforts made possible by Gilead 
Sciences, Inc. in partnership with the FOCUS Program. Gilead Sciences FOCUS program limits its support to testing and linkage to care. FOCUS does 



















• Male 50% 
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Results, continued  
• Proportion of patients with opioid code and an HIV code 
declined (1.9%) 
• Proportion of patients with opioid code and an HIV code and an 
HCV code declined (.52%)
• Proportion of total opioid poisoning codes remained stable 
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Results, continued
• Opioids + HCV proportion declined dramatically (43.3%, 35%, 
21.7%) 
• Suggests less people with HIV or HIV and HCV experienced 
poisoning due to injection or other opioids drug use during an 
interval when injection drug use in Georgia was rising   
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Discussion
• Data did not reflect assumptions 
– Very few mortalities 
– Relatively few cases with HIV + opioids, HIV + HCV + 
opioids 
– Decreases where we expected increases (to reflect rise 
in heroin use over time) 
– Males and females equally represented 
This research was supported (in whole or in part) by HCA and/or an HCA affiliated entity. The views expressed in this publication represent those of the 
author(s) and do not necessarily represent the official views of HCA or any of its affiliated entities. Screening program efforts made possible by Gilead 
Sciences, Inc. in partnership with the FOCUS Program. Gilead Sciences FOCUS program limits its support to testing and linkage to care. FOCUS does 
not support treatment and remains agnostic to partners' treatment decisions.
17
Discussion, continued
• Considerations for utilizing hospital EHR data 
– Sample size 
• Study design to net as many records as possible 
– Most HIV patients do not contract HIV from 
injection drug use4
• Longer retrospective time period
– Search terms 
• Investigate records with all opioids diagnoses (T40 
poisoning codes and F11 disorder codes) 
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Limitations
– ICD codes used for drug diagnoses may not be opioid-
specific 
– Opioid related disorder codes (F11 codes) were not queried  
– ICD codes reflected encounter complaints other than opioid 
poisoning (there for something else)
– Patient diagnostic codes may not reflect HIV and/or HCV 
status 
– Heroin not distinguished in all opioids code data 
– Some heroin users do not inject 
– Incidence rate vs. diagnosis rate (recent cases may not 
have surfaced in the ED data of patients living with opioid 
abuse) 
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